Digital Health Interests Of Pharma Giants Boehringer Ingelheim, Takeda, Astrazeneca, Amgen And Roche

With their extending reaches, resources and influence, pharmaceutical heavyweights have the potential to shape the digital health landscape to line up with their interests. And to have a better picture of where those interests lie, it is worth taking a look at what moves pharma giants are making in this sphere. With this in mind, we started a series of articles focusing on the digital health efforts of 14 global pharma companies.  The first article explored developments coming from Johnson & Johnson, Pfizer, Bayer and Novartis, while the second article investigated those coming from Merck, GlaxoSmithKline, AbbVie, Sanofi and Bristol Myers Squibb. This third article, which will conclude the series, will peek into the digital health trends that pharma giants Boehringer Ingelheim, Takeda, AstraZeneca, Amgen and Roche have taken an interest in. Boehringer Ingelheim: leaning on the patient side of the equation To boost opportunities for innovators and digital health tech uptake in the UK, pharma giant Boehringer Ingelheim (BI) launched a new guide in December 2020. It provides entrepreneurs with insights into the NHS, as well as potential pathways to sustainably improve the health system’s services with emerging technologies. BI has also made moves to improve the patient side of the digital health equation. Like its counterparts Pfizer and Bristol Myers Squibb, BI has developed a liking for digital therapeutics (DTx). In September 2020, the pharma compan...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: TMF Artificial Intelligence in Medicine Digital Health Research Future of Pharma sleep patient empowerment pharmaceutics roche MySugr Astra-Zeneca DTx takeda Boehringer Ingelheim Amgen digitisation Quire.ai Renalytix Eko Source Type: blogs